EP1265942A2 - Use of poly(diallylamine) polymers - Google Patents

Use of poly(diallylamine) polymers

Info

Publication number
EP1265942A2
EP1265942A2 EP00974674A EP00974674A EP1265942A2 EP 1265942 A2 EP1265942 A2 EP 1265942A2 EP 00974674 A EP00974674 A EP 00974674A EP 00974674 A EP00974674 A EP 00974674A EP 1265942 A2 EP1265942 A2 EP 1265942A2
Authority
EP
European Patent Office
Prior art keywords
polymer
diallylamine
poly
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00974674A
Other languages
German (de)
French (fr)
Other versions
EP1265942B1 (en
Inventor
John William Goodby
Alan William Hall
Paul Edward Young Milne
Keith Moray Blackwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qinetiq Ltd
Original Assignee
Qinetiq Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qinetiq Ltd filed Critical Qinetiq Ltd
Publication of EP1265942A2 publication Critical patent/EP1265942A2/en
Application granted granted Critical
Publication of EP1265942B1 publication Critical patent/EP1265942B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
    • C08G73/0611—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only one nitrogen atom in the ring, e.g. polypyrroles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G61/12—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule

Definitions

  • the present invention relates to the use of certain poly (diallylamine) polymers as bile acid removers.
  • Bile acid salts produced in the body from cholesterol, aid the digestion of dietary fats. They are usually reabsorbed into the bloodstream following digestion, which helps to conserve serum cholesterol levels. The cholesterol level can therefore be reduced by hindering reabsorption of the bile acids.
  • One way of doing this is to administer compounds which sequester the bile acids but cannot themselves be absorbed; the sequestered acids are then excreted and serum cholesterol is used up in the production of more bile acids.
  • WO 98/29107 describes certain poly (diallylamine) -based, hydrophobically-substituted bile acid sequestrants .
  • Our co-pending PCT application number PCT/GB99/02416 discloses certain diallylamine monomers and the polymers and copolymers derived from them.
  • a poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I below, or a pharmaceutically acceptable derivative of such a polymer, for use as a bile acid sequestrant/remover for administration to a human or animal patient, and/or for use in reducing serum cholesterol levels in a human or animal patient.
  • Derivatives of the polymer include for instance pharmaceutically acceptable salts thereof, co-ordination complexes for example with metal ions, hydrated forms, labelled forms for instance for use in diagnostic methods and pharmaceutical precursors which are convertible, either in vitro or in vivo, into the relevant polymer.
  • the polymer or derivative should ideally be in a form which is stable and non-absorbable in the patient, and of a molecular weight which enables it to reach the gastrointestinal tract and remain there sufficiently long for it to remove a significant amount of bile acid.
  • the invention provides the use of such a polymer or derivative in the preparation of a medicament for use as a bile acid sequestrant/remover for administration to a human or animal patient, and/or for use in reducing serum cholesterol levels in a human or animal patient.
  • third and fourth aspects provide, respectively: a) a poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I below, or a pharmaceutically acceptable derivative of such a polymer, for use in any surgical, therapeutic or diagnostic method practised on a human or animal patient, in particular a method related to bile acid and/or serum cholesterol levels in the patient; and b) the use of such a polymer or derivative in the preparation of a medicament for use in any surgical, therapeutic or diagnostic method practised on a human or animal patient, in particular a method related to bile acid and/or serum cholesterol levels in the patient.
  • a fifth aspect of the invention provides a method of treatment of a human or animal patient to reduce bile acid levels and/or to reduce serum cholesterol levels, the method comprising administering to the patient a therapeutically effective amount of a poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I, or of a pharmaceutically acceptable derivative of such a polymer.
  • a poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I, or of a pharmaceutically acceptable derivative of such a polymer.
  • the present invention provides a pharmaceutical composition containing a poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I, or a pharmaceutically acceptable derivative of such a polymer, together with a pharmaceutically acceptable excipient.
  • the composition may also contain one or more other pharmaceutically active ingredients for co-administration.
  • the polymer may be present in the form of a pharmaceutical composition according to this sixth aspect.
  • the polymer may be either a homopolymer, a copolymer or a composite polymer of the type described below.
  • R 1 and R 2 are independently selected from
  • R 7 R 8 n or a group CR 9 R 10 , - (CR 7 R 8 CR 9 R 10 ) or -(CR 5 R 10 CR 7 R 6 ) - where n is 0,1 or 2, R 7 and R 8 are independently selected from hydrogen or alkyl, R 1 and R 2 preferably being CH 2 .
  • R 9 and R10 may together form an electron withdrawing group.
  • R 3 and R 4 are independently selected from C, CH or CR 11 where R 11 is an electron withdrawing group, both preferably being CH.
  • suitable electron withdrawing groups R 9 and R 10 include COCH 2 CN and COCH 3 , and preferably R 9 and R 10 together form an oxo group.
  • R 11 is an electron withdrawing group, it is suitably COCH3.
  • the dotted lines indicate the presence or absence of a bond, preferably the absence, and X is a group CX X X 2 where the dotted line bond to which it is attached is absent and a group CX " where the dotted line bond to which it is attached is present, Y is a group CY 1 Y 2 where the dotted line bond to which it is attached is absent and a group CY 1 where the dotted line bond to which it is attached is present, and X 1 , X 2 , Y 1 and Y 2 are independently selected from hydrogen and fluorine.
  • X 1 , X 2 , Y 3 and Y 4 are all hydrogen.
  • R 5 is either a bond or an electron withdrawing group
  • R 6 is a bridging group of valency r
  • r is an integer of 3 or greater, suitably of from 3 to 6, preferably 3 or 4.
  • R 12 is H, or an optionally substituted hydrocarbyl group, for instance an alkyl group such as a C1-3 or C 3-24 alkyl. It is preferably a hydrophobic group such as a long chain (eg, a C 3 - C24) hydrocarbyl.
  • Z- is an anion of valency m, for example the conjugate base of a pharmaceutically acceptable acid, examples including halides (such as chloride or bromide) , citrate, tartrate, lactate, phosphate, hydrophosphate, methanesulphonate, acetate, formate, maleate, fumarate, malate, succinate, malonate, sulphate, hydrosulphate, L-glutamate, L-aspartate, pyruvate, mucate, benzoate, glucuronate, oxalate, ascorbate and acetylglycinate .
  • halides such as chloride or bromide
  • fluoride iodide
  • borides such as boron tetrafluoride
  • carboxylic acid esters such as those of formula R 14 C(0)0 ⁇ where R 14 is an optionally substituted hydrocarbyl group such as haloalkyl, in particular trifluoromethyl
  • anionic groups such as mesylate and tosylate.
  • n is 1 or 2.
  • networks are formed whose properties may be selected depending upon the precise nature of the R e group, the amount of diluent, plasticiser or chain terminator present and the polymerisation conditions employed. Polymerisation will occur in accordance with the general scheme set out in the accompanying Figure 1. Cross-linking in the polymer network occurs through the diene units, leading to a very stable material with robust physical properties .
  • the compound is designed such that it cyclopolymerises under the influence of ultraviolet or thermal radiation, preferably ultraviolet radiation.
  • Cyclopolymerisation may take place either spontaneously in the presence of the appropriate radiation or in the presence of a suitable initiator, for example 2, 2' -azobisisobutyronitrile (AIBN) , aromatic ketones such as benzophenones in particular acetophenone; chlorinated acetophenones such as di- or tri-chloroacetophenone; dialkoxyacetophenones such as dimethoxyacetophenones (sold under the Trade name "Irgacure 651”) ; dialkylhydroxyacetophenones such as dimethylhydroxyacetophenone (sold under the Trade name "Darocure 1173”) ; substituted dialkylhydroxyacetophenone alkyl ethers such as compounds of formula
  • AIBN 2, 2' -azobisisobutyronitrile
  • aromatic ketones such as benzophenones in particular aceto
  • R y is alkyl and in particular 2, 2-dimethylethyl
  • R x is hydroxy or halogen such as chloro
  • R c and R q are independently selected from alkyl or halogen such as chloro (examples of which are sold under the Trade names "Darocure 1116" and “Trigonal PI”) ; l-benzoylcyclohexanol-2 (sold under the Trade name "Irgacure 184”) ; benzoin or derivatives such as benzoin acetate, benzoin alkyl ethers in particular benzoin butyl ether, dialkoxybenzoins such as dimethoxybenzoin or deoxybenzoin; dibenzyl ketone; acyloxime esters such as methyl or ethyl esters of acyloxime (sold under the trade name "Quantaqure PDO”) ; acylphosphine oxides, acylphosphonates such as dialkylacyl
  • R is alkyl and Ar is an aryl group; dibenzoyl disulphides such as , 4' -dialkylbenzoyldisulphide; diphenyldithiocarbonate; benzophenone; 4, 4' -bis (N, N-dialkylamino) benzophenone; fluorenone; thioxanthone; benzil; or a compound of formula
  • the compound may be polymerised under the influence of a free radical or ion initiator as is understood in the art, as well as by application of an electron beam.
  • alkyl refers to straight or branched chain alkyl groups, suitably containing from 1 to 20 and preferably from 1 to 6 carbon atoms.
  • alkenyl and alkynyl refer to unsaturated straight or branched chains which include for example from 2-20 carbon atoms, for example from 2 to 6 carbon atoms . Chains may include one or more double or triple bonds respectively.
  • aryl refers to aromatic groups such as phenyl or naphthyl .
  • hydrocarbyl refers to any structure comprising carbon and hydrogen atoms.
  • these may be alkyl, alkenyl, alkynyl, aryl such as phenyl or napthyl, aralkyl, cycloalkyl, cycloalkenyl or cycloalkynyl .
  • they will contain up to 20 and preferably up to 10 carbon atoms.
  • heterocyclyl includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 10 ring atoms, at least one of which is a heteroatom such as oxygen, sulphur or nitrogen.
  • Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, iosquinolinyl , quinoxalinyl, benzthiazolyl, benzoxazolyl, benzothienyl or benzofuryl.
  • heteroatom refers to non-carbon atoms such as oxygen, nitrogen or sulphur atoms. Where nitrogen atoms are present, they will generally be present as part of an amino residue so that they will be substituted for example by hydrogen or alkyl.
  • amide is generally understood to refer to a group of formula C(0)NR a R b where R a and R b are hydrogen or an optionally substituted hydrocarbyl group.
  • sulphonamide correspondingly relates to groups of formula S(0)2NR a R b .
  • An electron withdrawing group or groups may be used in compounds of formula I to activate one or more of the double bonds in preparation for polymerisation. The nature of each electron withdrawing group will depend upon its position in relation to the double bond it is required to activate, as well as the nature of any other functional groups within the compound.
  • the diallyl amino nitrogen and R° together form an electron withdrawing group.
  • they may represent a group such as N + R 12 (Z ra ⁇ ) ⁇ /m , such as in formula la.
  • they may represent an amide or sulphonamide group where R 5 is a carbonyl or sulphonyl group such as C (0) or S(0) 2 .
  • R 6 will comprise a bridging group for example as is known in polymer chemistry. It may include straight or branched chain alkyl groups, optionally substituted or interposed with functional groups or siloxane groups such as alkyl siloxanes.
  • the bridging group R 6 may be aromatic or heteroaromatic, i.e. it may include one or more unsaturated carbon rings, optionally containing heteroatoms such as nitrogen, oxygen or sulphur.
  • the length of the bridging group will affect the properties of the polymeric material derived from the monomer. This can be used to design polymers with properties which are best suited to the application. For instance when the bridging group comprises relatively long chains, (for example with in excess of 6 repeat units, for example from 6-20 repeat units), the polymer will have pliable plastic properties. Alternatively, when the bridging group is relatively short, (e.g. less than 6 repeat units) the material will be more brittle.
  • the poly (diallylamine) polymer used in the various aspects of the present invention may be a homopolymer, or a copolymer derived from a mixture of a monomer of formula I or la with another monomer. Many such other monomers are known in the art; they may themselves include diallylamine compounds.
  • the polymer may also be a composite produced by polymerising a compound of formula I or la in the presence of another moiety such as graphite, an ether such as a crown ether or thioether, a phthalocyanine or a bipyridyl, all of which can produce composite polymers with modified properties.
  • a compound of formula I or la in the presence of another moiety such as graphite, an ether such as a crown ether or thioether, a phthalocyanine or a bipyridyl, all of which can produce composite polymers with modified properties.
  • the group R ⁇ may be a bridging group comprising a tetra or octa substituted non-linear optic unit such as an optionally substituted porphyrin or phthalocyanine.
  • Suitable optional substitutents in addition to the groups of formula I are hydrocarbyl groups such as alkyl in particular methyl.
  • An example of such a compound is a compound of formula II:
  • R ⁇ 21 , R , 2 ⁇ 2 , R , 2"3 and R are each groups of sub-formula III
  • R 25 , R 26 , R 27 and R 28 are each independently selected from hydrogen or hydrocarbyl groups such as alkyl and in particular methyl; the compound optionally contains a metal ion such as magnesium or zinc, within the macrocyclic heterocyclic unit; and
  • R 17 , R 18 , R 19 and R 20 are independently selected from groups of sub-formula IV:
  • a and b are independently selected from 0, 1 or 2
  • Z , Z and Z 3 are independently selected from a bond, an optionally substituted linear or branched alkyl or alkene chain wherein optionally one or more non-adjacent carbon atoms is replaced with a heteroatom or an amide group
  • Q 1 and Q 2 are independently selected from an optionally substituted carbocyclic or heterocyclic ring which optionally contains bridging alkyl groups .
  • Suitable carbocyclic rings for Q and Q 2 include cycloalkyl groups for example of from 1 to 20 carbon atoms.
  • Bridged carbocyclic ring structures include 1, 4-bicyclo [2.2.2] octane, decalin, bicyclo [2.2.1] heptane, cubane, diadamantane, adamantane.
  • Suitable heterocyclic rings include any of the above where one or more non adjacent carbon atoms are replaced by a heteroatom such as oxygen, sulphur or nitrogen (including amino or substituted amino), or a caboxyl or an amide group.
  • Suitable optional substitutents for the groups Q 1 and Q 2 include one or more groups selected from alkyl, alkenyl, alkynyl, aryl, aralkyl such as benzyl, or functional groups as defined above.
  • Particularly preferred substitutents for the groups Q 1 and Q ⁇ are oxo and halogen, in particular fluorine and chlorine.
  • Suitable optional substituents for the alkyl and alkene groups Z 1 , Z 2 and Z 3 include aryl, aralkyl and functional groups as defined above. Particular substituents include halogens such as fluorine and chlorine, and oxo. R , R , R and R may in particular be alkyl groups
  • An alternative compound is a compound of formula V:
  • R 50 through to R 65 are independently selected from hydrocarbyl in particular C1-12 alkyl, a group OR 65 where R 68 is hydrocarbyl in particular butyl, halogen in particular chlorine, or a group R 1 -R 24 where R 21 and R 24 are as defined in relation to formula II above, provided that at least three of R 50 to R 65 are R 21 -R 24 groups; and R ,66 and R are either hydrogen or together comprise a metal ion such as a copper magnesium or zinc ion,
  • R , R D R° and R 64 are halogen and R 50 ⁇ 5- j 3 j ⁇ p5J4' ⁇ p 5 5 7 7 D 58 TJ 61 D and R are independently C1-12 alkyl, C1-12 alkoxy or a group R "" -R 24
  • Polymerisation of a compound of formula II or V in accordance with the scheme of Figure 1, for example by photopolymerisation, will provide a cross-linked network polymer where the cross-linking occurs through the diene units for example as either quaternery ammonium salts or amides depending upon the particular nature of the groups R D present in the R 21 , R 22 , R 23 and R 24 units. Again this can produce a very stable network or elastomeric material with robust physical properties.
  • Pharmaceutically acceptable metals or metal ions may be inserted into the macrocyclic heterocyclic unit in order further to modify the polymer properties. Suitable metal ions include sodium, potassium, lithium, copper, zinc and iron ions.
  • a bridging group R is a polysiloxane network polymer where R 6 comprises a straight or branched siloxane chain of valency r or a cyclic polysiloxane unit.
  • R , R , R , R" u , R" 1 , R and R are as defined above in relation to formula II;
  • R 28 , R 29 , R 30 are R 31 are selected from hydrocarbyl such as alkyl and in particular methyl; and s is 0 or an integer of 1 or more, for example from 1 to 5.
  • formula VI has four siloxane units in the ring (i.e. s is 1) . It will be appreciated that there may be other numbers of such units in the cyclic ring, for example from 3 to 8 siloxane units (s is from 0 to 5) , preferably from 3 to 6 siloxane units (s is from 0 to 3) .
  • R 23 as defined in relation to formula II
  • compounds of formula VI, or variants thereof will form a cross-linked network where the cross- linking occurs through the groups R **1 , R 22 , R and R "4 as illustrated in Figure 1.
  • Such polymers may be coated onto surfaces and polymerised in situ, for example using radiation curing.
  • R 17 , R 18 ,R 19 , R 20 , R 21 , R 22 , R 23 and R 24 are as defined above in relation to formula II.
  • Particularly preferred polymers for use in the various aspects of the present invention are those derived from the monomers prepared in accordance with the experimental examples below.
  • Compounds of formula I are suitably prepared by conventional methods, for example by reacting a compound of formula VIII:
  • X 1 , X 2 , Y 1 , Y 2 , R 1 , R2, R 2 and R 4 are as defined in relation to formula I, W is a nitrogen atom or a substituted a ine group as described above or a suitable precursor thereof, and R ,35 is hydrogen or hydroxy, with a compound of formula IX :
  • R , R and r are as defined in relation to formula I and Z 4 is a leaving group, and thereafter if desired or necessary converting a precursor group W to the desired amine form.
  • Suitable leaving groups Z include halogen, in particular bromo, mesylate or tosylate.
  • the reaction is suitably effected in an organic solvent such as tetrahydrofuran, dichloromethane, toluene, an alcohol such as methanol or ethanol, or a ketone such as butanone, and at elevated temperatures for example near the boiling point of the solvent.
  • reaction is effected in the presence of a base such as potassium carbonate.
  • W When the group W is a precursor of the desired amine, it may be converted to the desired form using conventional techniques.
  • W may be a nitrogen atom, which may be converted to a group NR 12 (Z ⁇ ) ⁇ m , where R 12 , Z and m are as defined above, by reaction with an appropriate salt under conventional conditions .
  • the pharmaceutical composition of the sixth aspect of the invention may include pharmaceutically acceptable adjuvants such as carriers, buffers, stabilisers, coatings or other agents to prevent premature degradation or to delay release, taste masking agents or any other excipients, depending on the purpose of the composition and its intended route of administration (eg, oral, intravenous or whatever) . It may additionally include other pharmaceutically active ingredients, which may be therapeutically (including prophylactically) active or have some diagnostic function. It may for instance contain one or more other bile acid removing agents .
  • pharmaceutically acceptable adjuvants such as carriers, buffers, stabilisers, coatings or other agents to prevent premature degradation or to delay release, taste masking agents or any other excipients, depending on the purpose of the composition and its intended route of administration (eg, oral, intravenous or whatever) .
  • It may additionally include other pharmaceutically active ingredients, which may be therapeutically (including prophylactically) active or have some diagnostic function. It may for instance contain one or more other bile acid removing agents .
  • the composition may be in any suitable form, such as a tablet, capsule, powder, solution or suspension. Conventional solid or liquid carriers may be used in such formulations.
  • concentration of the poly (diallylamine) polymer contained in the pharmaceutical composition will depend, of course, on the nature and severity of the condition to be treated or diagnosed using the composition, and on the patient to whom and method by which it is to be administered. Possible uses for the pharmaceutical composition include both therapeutic and diagnostic uses. In particular, it may be used to treat and/or diagnose any condition which is related to (ie, which is or can be caused or mediated, directly or indirectly, by, or which is in any way associated with) the presence of bile acids, such as a high serum cholesterol level.
  • a therapeutic treatment method in which the poly (diallylamine) polymer may be used involves the administration to a patient suffering from a relevant condition of a therapeutically (which includes prophylactically) effective amount of the polymer, preferably in the form of a pharmaceutical composition according to the sixth aspect of the invention.
  • Effective amount means an amount sufficient to cause a benefit (which may be prophylactic) to the patient or at least to cause a change in the patient's condition, ie, usually to cause a medically significant reduction in the patient's bile acid and/or serum cholesterol levels.
  • the actual amount administered to the patient, and the rate and time-course of administration will depend on the nature of the patient, the nature and severity of the condition, the administration method used, etc...
  • the polymer may be administered alone or in combination with other treatments, either simultaneously or sequentially. It may be administered by any suitable route, preferably orally. It may be administered directly to a suitable site or in a manner in which it targets a particular site - suitable targeting methods are already known.
  • a diagnostic method might involve the use of the polymer or a derivative thereof, to determine, either qualitatively or quantitatively, the existence of a particular medical condition or change in condition. Such a method may be carried out either in vi tro or in vivo . One or more of the materials used in the method may be appropriately labelled.
  • a seventh aspect of the present invention there is provided a method for producing a pharmaceutical composition according to the sixth aspect, said method comprising causing a monomer of formula I or la to polymerise. The resultant polymer may then be admixed with one or more pharmaceutically acceptable adjuvants, and/or with one or more other therapeutically or diagnostically active agents.
  • the monomer is a radiation curable compound and polymerisation is effected by subjecting the compound to the appropriate radiation (e.g. heat or ultraviolet radiation) and if necessary in the presence of a suitable initiator such as a photoinitiator like AIBN.
  • a suitable initiator such as a photoinitiator like AIBN.
  • the compounds of formula I or la link together by way of the unsaturated bonds such as the diene groups, as illustrated in Figure 1. Because the compounds include at least two diene groups, they will tend to become cross-linked to form a network or three dimensional structure.
  • the degree of cross-linking can be controlled by carrying out the polymerisation in the presence of cross- linkers, where for example r is 4, or diluents, plasticisers or chain terminators.
  • cross- linkers where for example r is 4, or diluents, plasticisers or chain terminators.
  • the polymers obtained from monomers of the general formula I or la have the general formula XI :
  • A is a bond or CH 2 , R 1 , R 2 , R 3 , R 4 and R 5 are as defined in relation to formula I, and R 6' is a group of formula R 6 as defined in formula I which is substituted by at least one further group of sub formula XII:
  • An advantage of working with monomers of formula I is that they may be applied to a desired substrate and caused to polymerise in situ, thus increasing ease of processing.
  • a further advantage is their versatility, allowing a wide range of desired physicochemical properties to be built into the polymers formed from them.
  • either amorphous or ordered systems can be prepared depending upon the polymerisation conditions used. Copolymerisation can also be used to affect the physical properties of the end product.
  • Systems can be prepared which mimic conventional polymers, or which involve donor/acceptor systems.
  • the polymers can be produced in a range of physical forms, including films and coatings, using heat or radiation curing techniques if desired.
  • Figure 1 illustrates the way in which compounds of the general formula I may cyclopolymerise to form polymers of use in the present invention
  • Figure 2 illustrates the production of a network polymer of a type which may be of use in the invention.
  • Ir vmax (thin film) 3323, 3086, 2935, 2861, 1650, 1545, 1416, 1363, 1228, 1135, 994, 925, 556 cm '1
  • Amide A (23.21g, 0.11 mol), pentaerythritol (3.75g, 0.028 mol), dicyclohexylcarbodiimide (22.70g, 0.11 mol) and 4- dimethylaminopyridine (0.50g) were placed in
  • Tris (2-aminoethyl) amine (2.08g, 0.0142 mol) and dicyclohexylcarbodiimide (8.87g, 0.043 mol) were placed in dry dichloromethane (100 cm 3 ) and stirred at room temperature.
  • Amide A (9.0g, 0.043 mol) in dry dichloromethane (20 cm 3 ) was added dropwise over 30 minutes and the whole was left to stir for five days.
  • the dicyclohexylurea was removed by filtration (Whatman No. 1 filter paper) and the solvent removed in vacuo to leave a yellow oil.
  • the oil was purified using chromatography (ethyl acetate followed by methanol) Removal of solvent gave a pale yellow oil, 8.94g, 87%.
  • Ir vmax (thin film): 3321 (s), 3086, 2934, 1620, 1551, 1420, 1358, 1234, 1136, 1060, 994, 927, 756, 665, 560 cm "1 .
  • Triethanolamine (5.10g, 0.034 mol), Amide A (20. Og, 0.10 mol), dicyclohexylcarbodiimide (20.60g, 0.10 mol) and 4- dimethylaminopyridine (0.5g) were dissolved in dry dichloromethane and the solution stirred for 48 hours.
  • the resultant dicyclohexylurea was removed by filtration and the solvent removed in vacuo to leave a yellow oil.
  • the oil was redissolved in dichloromethane and washed with 3M HCl solution (100 ml), then brine (100 ml), then dried over MgS0 4 .
  • Ir vmax (thin film): 3087, 2932, 1738, 1654, 1416, 1223, 1169, 995, 927, 755, 666, 557 cm "1 .
  • Citric acid (10. Og, 0.048 mol) and diallylamine (14. Og, 0.145 mol) were carefully placed in 25 cm 3 THF-Dichloromethane (1:1) and stirred for 30 minutes.
  • Dicyclohexylcarbodiimide (25 cm3) (30. Og, 0.145 mol) was added slowly and carefully to the reaction mixture.
  • 4-dimethylaminopyridine (l.Og) was added and the mixture was stirred at room temperature for 8 days.
  • Thin layer chromatography ethyl acetate showed a major new product and several smaller ones.
  • the dicyclohexylurea was removed by filtration (Whatman No. 1 filter paper) and the solvent removed in vacuo to leave a yellow oil.
  • Monomers A (0.5g) and B (0.025g) were dissolved with the Irgacure 184 (25mg) in dry dichloromethane (2 cm 3 ) and the solution spread over an area 3 x 7 cm on a plate glass plate. The solvent was allowed to evaporate to leave a thin monomer film which was irradiated with a Philips UVA (75w) sunlamp for 1 hour. The resultant hard polymer film was washed with dry dichloromethane (20 cm 3 ) to remove surface stickiness and allowed to dry in air.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A poly(diallylamine)polymer pharmaceutical composition or pharmaceutical derivate used to sequester bile acid and/or to reduce serum cholesterol levels. The polymer is derived from a monomer of formula Ia, where R6 is a bridging group of valency r, and r is an integer of 3 or greater to provide a cross linked polymer, and all diallyl nitrogen atoms are linked to at least two further diallyl nitrogen atoms.

Description

Use of poly (diallylamine) polymers
The present invention relates to the use of certain poly (diallylamine) polymers as bile acid removers.
Bile acid salts, produced in the body from cholesterol, aid the digestion of dietary fats. They are usually reabsorbed into the bloodstream following digestion, which helps to conserve serum cholesterol levels. The cholesterol level can therefore be reduced by hindering reabsorption of the bile acids. One way of doing this is to administer compounds which sequester the bile acids but cannot themselves be absorbed; the sequestered acids are then excreted and serum cholesterol is used up in the production of more bile acids.
WO 98/29107 describes certain poly (diallylamine) -based, hydrophobically-substituted bile acid sequestrants . Our co-pending PCT application number PCT/GB99/02416 discloses certain diallylamine monomers and the polymers and copolymers derived from them.
According to a first aspect of the present invention, there is provided a poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I below, or a pharmaceutically acceptable derivative of such a polymer, for use as a bile acid sequestrant/remover for administration to a human or animal patient, and/or for use in reducing serum cholesterol levels in a human or animal patient.
Derivatives of the polymer include for instance pharmaceutically acceptable salts thereof, co-ordination complexes for example with metal ions, hydrated forms, labelled forms for instance for use in diagnostic methods and pharmaceutical precursors which are convertible, either in vitro or in vivo, into the relevant polymer.
The polymer or derivative should ideally be in a form which is stable and non-absorbable in the patient, and of a molecular weight which enables it to reach the gastrointestinal tract and remain there sufficiently long for it to remove a significant amount of bile acid.
According to a second aspect, the invention provides the use of such a polymer or derivative in the preparation of a medicament for use as a bile acid sequestrant/remover for administration to a human or animal patient, and/or for use in reducing serum cholesterol levels in a human or animal patient.
Since the present invention is based on the first medical indication for polymers of this type, third and fourth aspects provide, respectively: a) a poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I below, or a pharmaceutically acceptable derivative of such a polymer, for use in any surgical, therapeutic or diagnostic method practised on a human or animal patient, in particular a method related to bile acid and/or serum cholesterol levels in the patient; and b) the use of such a polymer or derivative in the preparation of a medicament for use in any surgical, therapeutic or diagnostic method practised on a human or animal patient, in particular a method related to bile acid and/or serum cholesterol levels in the patient.
The term "therapy" as used here includes prophylaxis. A fifth aspect of the invention provides a method of treatment of a human or animal patient to reduce bile acid levels and/or to reduce serum cholesterol levels, the method comprising administering to the patient a therapeutically effective amount of a poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I, or of a pharmaceutically acceptable derivative of such a polymer.
According to a sixth aspect, the present invention provides a pharmaceutical composition containing a poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I, or a pharmaceutically acceptable derivative of such a polymer, together with a pharmaceutically acceptable excipient. The composition may also contain one or more other pharmaceutically active ingredients for co-administration. In accordance with the fifth aspect of the invention, the polymer may be present in the form of a pharmaceutical composition according to this sixth aspect.
In all aspects of the invention, the polymer may be either a homopolymer, a copolymer or a composite polymer of the type described below.
The monomer of the general formula I is shown below.
It may alternatively have the form shown below as la.
In formulae I and la, R1 and R2 are independently selected from
; CR7R8 n, or a group CR9R10, - (CR7R8CR9R10) or -(CR5R10CR7R6) - where n is 0,1 or 2, R7 and R8 are independently selected from hydrogen or alkyl, R1 and R2 preferably being CH2. One of R9 or
,ιo may be hydrogen and the other an electron withdrawing group, or R 9 and R10 may together form an electron withdrawing group. R3 and R4 are independently selected from C, CH or CR11 where R11 is an electron withdrawing group, both preferably being CH. Where R1 and/or R2 are electron withdrawing, activating groups, suitable electron withdrawing groups R9 and R10 include COCH2CN and COCH3, and preferably R9 and R10 together form an oxo group. Where R11 is an electron withdrawing group, it is suitably COCH3. The dotted lines indicate the presence or absence of a bond, preferably the absence, and X is a group CXXX2 where the dotted line bond to which it is attached is absent and a group CX" where the dotted line bond to which it is attached is present, Y is a group CY1Y2 where the dotted line bond to which it is attached is absent and a group CY1 where the dotted line bond to which it is attached is present, and X1, X2, Y1 and Y2 are independently selected from hydrogen and fluorine. Preferably, X1, X2, Y3 and Y4 are all hydrogen.
R5 is either a bond or an electron withdrawing group; R6 is a bridging group of valency r; and r is an integer of 3 or greater, suitably of from 3 to 6, preferably 3 or 4.
R12 is H, or an optionally substituted hydrocarbyl group, for instance an alkyl group such as a C1-3 or C 3-24 alkyl. It is preferably a hydrophobic group such as a long chain (eg, a C3- C24) hydrocarbyl.
Z- is an anion of valency m, for example the conjugate base of a pharmaceutically acceptable acid, examples including halides (such as chloride or bromide) , citrate, tartrate, lactate, phosphate, hydrophosphate, methanesulphonate, acetate, formate, maleate, fumarate, malate, succinate, malonate, sulphate, hydrosulphate, L-glutamate, L-aspartate, pyruvate, mucate, benzoate, glucuronate, oxalate, ascorbate and acetylglycinate . Other examples include fluoride, iodide, borides such as boron tetrafluoride; carboxylic acid esters such as those of formula R14C(0)0~ where R14 is an optionally substituted hydrocarbyl group such as haloalkyl, in particular trifluoromethyl; and other anionic groups such as mesylate and tosylate.
Preferably, where R1 and R2 are both (CR7R8)n, at least one n is 1 or 2. Suitably in formula I, n is 1 or 2.
On polymerisation of a compound of formula I or la, networks are formed whose properties may be selected depending upon the precise nature of the Re group, the amount of diluent, plasticiser or chain terminator present and the polymerisation conditions employed. Polymerisation will occur in accordance with the general scheme set out in the accompanying Figure 1. Cross-linking in the polymer network occurs through the diene units, leading to a very stable material with robust physical properties .
Suitably the compound is designed such that it cyclopolymerises under the influence of ultraviolet or thermal radiation, preferably ultraviolet radiation. Cyclopolymerisation may take place either spontaneously in the presence of the appropriate radiation or in the presence of a suitable initiator, for example 2, 2' -azobisisobutyronitrile (AIBN) , aromatic ketones such as benzophenones in particular acetophenone; chlorinated acetophenones such as di- or tri-chloroacetophenone; dialkoxyacetophenones such as dimethoxyacetophenones (sold under the Trade name "Irgacure 651") ; dialkylhydroxyacetophenones such as dimethylhydroxyacetophenone (sold under the Trade name "Darocure 1173") ; substituted dialkylhydroxyacetophenone alkyl ethers such as compounds of formula
Rq
where Ry is alkyl and in particular 2, 2-dimethylethyl, Rx is hydroxy or halogen such as chloro, and Rc and Rq are independently selected from alkyl or halogen such as chloro (examples of which are sold under the Trade names "Darocure 1116" and "Trigonal PI") ; l-benzoylcyclohexanol-2 (sold under the Trade name "Irgacure 184") ; benzoin or derivatives such as benzoin acetate, benzoin alkyl ethers in particular benzoin butyl ether, dialkoxybenzoins such as dimethoxybenzoin or deoxybenzoin; dibenzyl ketone; acyloxime esters such as methyl or ethyl esters of acyloxime (sold under the trade name "Quantaqure PDO") ; acylphosphine oxides, acylphosphonates such as dialkylacylphosphonate, ketosulphides for example of formula
R* where R: is alkyl and Ar is an aryl group; dibenzoyl disulphides such as , 4' -dialkylbenzoyldisulphide; diphenyldithiocarbonate; benzophenone; 4, 4' -bis (N, N-dialkylamino) benzophenone; fluorenone; thioxanthone; benzil; or a compound of formula
where Ar is an aryl group such as phenyl and R= is alkyl such as methyl (sold under the trade name "Speedcure B DS") . The compound may be polymerised under the influence of a free radical or ion initiator as is understood in the art, as well as by application of an electron beam.
As used herein, the term "alkyl" refers to straight or branched chain alkyl groups, suitably containing from 1 to 20 and preferably from 1 to 6 carbon atoms. The terms "alkenyl" and "alkynyl" refer to unsaturated straight or branched chains which include for example from 2-20 carbon atoms, for example from 2 to 6 carbon atoms . Chains may include one or more double or triple bonds respectively. In addition, the term "aryl" refers to aromatic groups such as phenyl or naphthyl .
The term "hydrocarbyl" refers to any structure comprising carbon and hydrogen atoms. For example, these may be alkyl, alkenyl, alkynyl, aryl such as phenyl or napthyl, aralkyl, cycloalkyl, cycloalkenyl or cycloalkynyl . Suitably they will contain up to 20 and preferably up to 10 carbon atoms. The term "heterocyclyl" includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 10 ring atoms, at least one of which is a heteroatom such as oxygen, sulphur or nitrogen. Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, iosquinolinyl , quinoxalinyl, benzthiazolyl, benzoxazolyl, benzothienyl or benzofuryl.
The term "functional group" refers to reactive groups such as halo, cyano, nitro, oxo, C(0)nRs, ORa, S(0)tRa, NR°R , OC(0)NRDRc, C(0)NRbRc, OC(0)NRbRc, -NR7C(0)nR6, -NRaCONRbRc, -C=NORa, -N=CRRc, S(0)tNRDRc, C(S)nRa, C(S)ORa, C(S)NRbRc or -NRbS(0)tRa where Ra , Rb and Rc are independently selected from hydrogen or optionally substituted hydrocarbyl, or Rb and Rc together form an optionally substituted ring which optionally contains further heteroatoms such as S(0)s, oxygen and nitrogen, n is an integer of 1 or 2, t is 0 or an integer of 1-3. In particular the functional groups are groups such as halo, cyano, nitro, oxo, C(0)nRa, ORa, S(0)tRa, NRbRc, OC(0)NRbRc, C(0)NRbRc, OC(0)NRbRc, - NR7C(0)nR6, -NRaCONRbRc, -NRaCSNRbRc, -C=NORa, -N=CRbRc, S(0)tNRRc, , or -NRbS(0)tRa where R5 , Rb and Rc, n and t are as defined above .
The term "heteroatom" as used herein refers to non-carbon atoms such as oxygen, nitrogen or sulphur atoms. Where nitrogen atoms are present, they will generally be present as part of an amino residue so that they will be substituted for example by hydrogen or alkyl.
The term "amide" is generally understood to refer to a group of formula C(0)NRaRb where Ra and Rb are hydrogen or an optionally substituted hydrocarbyl group. The term "sulphonamide" correspondingly relates to groups of formula S(0)2NRaRb. An electron withdrawing group or groups may be used in compounds of formula I to activate one or more of the double bonds in preparation for polymerisation. The nature of each electron withdrawing group will depend upon its position in relation to the double bond it is required to activate, as well as the nature of any other functional groups within the compound.
In a preferred embodiment, the diallyl amino nitrogen and R° together form an electron withdrawing group. For example, they may represent a group such as N+R12 (Zra~) ι/m, such as in formula la. Alternatively, they may represent an amide or sulphonamide group where R5 is a carbonyl or sulphonyl group such as C (0) or S(0)2.
The properties of the polymer obtained from a monomer of formula I or la will depend upon a variety of factors. For instance, the nature of the anion Z will affect the physical properties of the polymer such as its porosity, water retention and conductivity. The nature of the group R6 also has a significant effect. Suitably R6 will comprise a bridging group for example as is known in polymer chemistry. It may include straight or branched chain alkyl groups, optionally substituted or interposed with functional groups or siloxane groups such as alkyl siloxanes.
Optionally the bridging group R6 may be aromatic or heteroaromatic, i.e. it may include one or more unsaturated carbon rings, optionally containing heteroatoms such as nitrogen, oxygen or sulphur.
The length of the bridging group will affect the properties of the polymeric material derived from the monomer. This can be used to design polymers with properties which are best suited to the application. For instance when the bridging group comprises relatively long chains, (for example with in excess of 6 repeat units, for example from 6-20 repeat units), the polymer will have pliable plastic properties. Alternatively, when the bridging group is relatively short, (e.g. less than 6 repeat units) the material will be more brittle. The poly (diallylamine) polymer used in the various aspects of the present invention may be a homopolymer, or a copolymer derived from a mixture of a monomer of formula I or la with another monomer. Many such other monomers are known in the art; they may themselves include diallylamine compounds.
The polymer may also be a composite produced by polymerising a compound of formula I or la in the presence of another moiety such as graphite, an ether such as a crown ether or thioether, a phthalocyanine or a bipyridyl, all of which can produce composite polymers with modified properties.
The group Rε may be a bridging group comprising a tetra or octa substituted non-linear optic unit such as an optionally substituted porphyrin or phthalocyanine. Suitable optional substitutents in addition to the groups of formula I are hydrocarbyl groups such as alkyl in particular methyl. An example of such a compound is a compound of formula II:
where R ι 21 , R , 2~2 , R , 2"3 and R are each groups of sub-formula III
where X1, X Y1, Y , R1, R RJ, R" and R° are as defined in relation to formula I; R25, R26, R27 and R28 are each independently selected from hydrogen or hydrocarbyl groups such as alkyl and in particular methyl; the compound optionally contains a metal ion such as magnesium or zinc, within the macrocyclic heterocyclic unit; and
R17, R18, R19 and R20 are independently selected from groups of sub-formula IV:
where a and b are independently selected from 0, 1 or 2, Z , Z and Z3 are independently selected from a bond, an optionally substituted linear or branched alkyl or alkene chain wherein optionally one or more non-adjacent carbon atoms is replaced with a heteroatom or an amide group, Q1 and Q2 are independently selected from an optionally substituted carbocyclic or heterocyclic ring which optionally contains bridging alkyl groups .
Suitable carbocyclic rings for Q and Q2 include cycloalkyl groups for example of from 1 to 20 carbon atoms. Bridged carbocyclic ring structures include 1, 4-bicyclo [2.2.2] octane, decalin, bicyclo [2.2.1] heptane, cubane, diadamantane, adamantane. Suitable heterocyclic rings include any of the above where one or more non adjacent carbon atoms are replaced by a heteroatom such as oxygen, sulphur or nitrogen (including amino or substituted amino), or a caboxyl or an amide group. Suitable optional substitutents for the groups Q1 and Q2 include one or more groups selected from alkyl, alkenyl, alkynyl, aryl, aralkyl such as benzyl, or functional groups as defined above. Particularly preferred substitutents for the groups Q1 and Q~ are oxo and halogen, in particular fluorine and chlorine.
Suitable optional substituents for the alkyl and alkene groups Z1, Z2 and Z3 include aryl, aralkyl and functional groups as defined above. Particular substituents include halogens such as fluorine and chlorine, and oxo. R , R , R and R may in particular be alkyl groups An alternative compound is a compound of formula V:
where R50 through to R65 are independently selected from hydrocarbyl in particular C1-12 alkyl, a group OR65 where R68 is hydrocarbyl in particular butyl, halogen in particular chlorine, or a group R1-R24 where R21 and R24 are as defined in relation to formula II above, provided that at least three of R50 to R65 are R21-R24 groups; and R ,66 and R are either hydrogen or together comprise a metal ion such as a copper magnesium or zinc ion, Preferably in formula V, R , RD R° and R64 are halogen and R50 π 5-j3j π p5J4' ^ p 5577 D 58 TJ 61 D and R are independently C1-12 alkyl, C1-12 alkoxy or a group R""-R 24
Polymerisation of a compound of formula II or V in accordance with the scheme of Figure 1, for example by photopolymerisation, will provide a cross-linked network polymer where the cross-linking occurs through the diene units for example as either quaternery ammonium salts or amides depending upon the particular nature of the groups RD present in the R21, R22, R23 and R24 units. Again this can produce a very stable network or elastomeric material with robust physical properties. Pharmaceutically acceptable metals or metal ions may be inserted into the macrocyclic heterocyclic unit in order further to modify the polymer properties. Suitable metal ions include sodium, potassium, lithium, copper, zinc and iron ions. Yet a further possibility for a bridging group R is a polysiloxane network polymer where R6 comprises a straight or branched siloxane chain of valency r or a cyclic polysiloxane unit.
Thus the monomer of general formula I may have the structure VI:
where R , R , R , R"u, R"1, R and R are as defined above in relation to formula II;
R28, R29, R30 are R31 are selected from hydrocarbyl such as alkyl and in particular methyl; and s is 0 or an integer of 1 or more, for example from 1 to 5.
In a particular embodiment, formula VI has four siloxane units in the ring (i.e. s is 1) . It will be appreciated that there may be other numbers of such units in the cyclic ring, for example from 3 to 8 siloxane units (s is from 0 to 5) , preferably from 3 to 6 siloxane units (s is from 0 to 3) .
In the above structure VI, it will be appreciated that -Si- may be replaced by B or B~; or -Si-O- may be replaced by -B-N(R4")- where R40 is a hydrocarbyl group such as a group of formula Rx9 -
R 23 as defined in relation to formula II Upon polymerisation, compounds of formula VI, or variants thereof, will form a cross-linked network where the cross- linking occurs through the groups R**1, R22, R and R"4 as illustrated in Figure 1. Such polymers may be coated onto surfaces and polymerised in situ, for example using radiation curing.
Further examples of compounds of formula I include compounds of formula VII:
where R17, R18,R19, R20, R21, R22, R23 and R24 are as defined above in relation to formula II.
Particular examples of compounds of formula I and related compounds are listed in Table 1 below.
Table 1
where - indicates a bond and Me is an abbreviation for methyl.
Particularly preferred polymers for use in the various aspects of the present invention are those derived from the monomers prepared in accordance with the experimental examples below. Compounds of formula I are suitably prepared by conventional methods, for example by reacting a compound of formula VIII:
where X1, X2, Y1, Y2, R1, R2, R2 and R4 are as defined in relation to formula I, W is a nitrogen atom or a substituted a ine group as described above or a suitable precursor thereof, and R ,35 is hydrogen or hydroxy, with a compound of formula IX :
R6- [R5-Z4] r ( IX)
where R , R and r are as defined in relation to formula I and Z4 is a leaving group, and thereafter if desired or necessary converting a precursor group W to the desired amine form.
Suitable leaving groups Z include halogen, in particular bromo, mesylate or tosylate. The reaction is suitably effected in an organic solvent such as tetrahydrofuran, dichloromethane, toluene, an alcohol such as methanol or ethanol, or a ketone such as butanone, and at elevated temperatures for example near the boiling point of the solvent.
Preferably the reaction is effected in the presence of a base such as potassium carbonate.
When the group W is a precursor of the desired amine, it may be converted to the desired form using conventional techniques. For example W may be a nitrogen atom, which may be converted to a group NR12 (Z~) ιm, where R12, Z and m are as defined above, by reaction with an appropriate salt under conventional conditions .
Compounds of formulae VIII and IX are either known compounds or they can be prepared from known compounds by conventional methods .
The pharmaceutical composition of the sixth aspect of the invention may include pharmaceutically acceptable adjuvants such as carriers, buffers, stabilisers, coatings or other agents to prevent premature degradation or to delay release, taste masking agents or any other excipients, depending on the purpose of the composition and its intended route of administration (eg, oral, intravenous or whatever) . It may additionally include other pharmaceutically active ingredients, which may be therapeutically (including prophylactically) active or have some diagnostic function. It may for instance contain one or more other bile acid removing agents .
The composition may be in any suitable form, such as a tablet, capsule, powder, solution or suspension. Conventional solid or liquid carriers may be used in such formulations. The concentration of the poly (diallylamine) polymer contained in the pharmaceutical composition will depend, of course, on the nature and severity of the condition to be treated or diagnosed using the composition, and on the patient to whom and method by which it is to be administered. Possible uses for the pharmaceutical composition include both therapeutic and diagnostic uses. In particular, it may be used to treat and/or diagnose any condition which is related to (ie, which is or can be caused or mediated, directly or indirectly, by, or which is in any way associated with) the presence of bile acids, such as a high serum cholesterol level.
A therapeutic treatment method in which the poly (diallylamine) polymer may be used involves the administration to a patient suffering from a relevant condition of a therapeutically (which includes prophylactically) effective amount of the polymer, preferably in the form of a pharmaceutical composition according to the sixth aspect of the invention. "Effective amount" means an amount sufficient to cause a benefit (which may be prophylactic) to the patient or at least to cause a change in the patient's condition, ie, usually to cause a medically significant reduction in the patient's bile acid and/or serum cholesterol levels. The actual amount administered to the patient, and the rate and time-course of administration, will depend on the nature of the patient, the nature and severity of the condition, the administration method used, etc... Appropriate values can be selected by the trained medical practitioner. The polymer may be administered alone or in combination with other treatments, either simultaneously or sequentially. It may be administered by any suitable route, preferably orally. It may be administered directly to a suitable site or in a manner in which it targets a particular site - suitable targeting methods are already known.
A diagnostic method according to the invention might involve the use of the polymer or a derivative thereof, to determine, either qualitatively or quantitatively, the existence of a particular medical condition or change in condition. Such a method may be carried out either in vi tro or in vivo . One or more of the materials used in the method may be appropriately labelled. According to a seventh aspect of the present invention there is provided a method for producing a pharmaceutical composition according to the sixth aspect, said method comprising causing a monomer of formula I or la to polymerise. The resultant polymer may then be admixed with one or more pharmaceutically acceptable adjuvants, and/or with one or more other therapeutically or diagnostically active agents.
Suitably the monomer is a radiation curable compound and polymerisation is effected by subjecting the compound to the appropriate radiation (e.g. heat or ultraviolet radiation) and if necessary in the presence of a suitable initiator such as a photoinitiator like AIBN. Where the monomer cannot be cured in this way, or it would be inappropriate to do so, other conventional polymerisation techniques can be employed as would be understood in the art.
During the polymerisation process, the compounds of formula I or la link together by way of the unsaturated bonds such as the diene groups, as illustrated in Figure 1. Because the compounds include at least two diene groups, they will tend to become cross-linked to form a network or three dimensional structure. The degree of cross-linking can be controlled by carrying out the polymerisation in the presence of cross- linkers, where for example r is 4, or diluents, plasticisers or chain terminators. These will suitably comprise a compound of formula X:
where X1, X2, Y1, Y2, R1, R2, R3, R4, R5, R6 and r are as defined in relation to formula I . Compounds of formula I may be used in the preparation of homopolymers, or of copolymers where they are mixed with other monomeric units which may themselves be of formula I or otherwise. A general scheme illustrating the sort of polymerisation process which may occur using a polyethylene type bridging group is illustrated in Figure 2.
The polymers obtained from monomers of the general formula I or la have the general formula XI :
where A is a bond or CH2, R1, R2, R3, R4 and R5 are as defined in relation to formula I, and R6' is a group of formula R6 as defined in formula I which is substituted by at least one further group of sub formula XII:
where y is an integer in excess of 1, preferably in excess of 5 and suitably from 5 to 30 and A is as defined above. It will be understood that copolymers also fall within the scope of this definition as outlined above.
To form the polymers of use in the present invention, it is possible to take a suitable organic system that has optimal or optimised properties for use in a desired application and to
structurally modify the system by the incorporation of diallylamino groups, thus introducing not only bile acid sequestering properties but also a ready ability to polymerise, in particular using heat or light curing. A three dimensional network can then be created that will have properties associated with the parent organic system.
An advantage of working with monomers of formula I is that they may be applied to a desired substrate and caused to polymerise in situ, thus increasing ease of processing.
A further advantage is their versatility, allowing a wide range of desired physicochemical properties to be built into the polymers formed from them. In particular, either amorphous or ordered systems can be prepared depending upon the polymerisation conditions used. Copolymerisation can also be used to affect the physical properties of the end product. Systems can be prepared which mimic conventional polymers, or which involve donor/acceptor systems. The polymers can be produced in a range of physical forms, including films and coatings, using heat or radiation curing techniques if desired.
The invention will now be particularly described by way of example with reference to the accompanying diagrammatic drawings in which:
Figure 1 illustrates the way in which compounds of the general formula I may cyclopolymerise to form polymers of use in the present invention; and
Figure 2 illustrates the production of a network polymer of a type which may be of use in the invention.
The following experimental examples illustrate the preparation of monomers of the general formula I and polymers derived from them, which polymers may be used in the various aspects of the present invention.
Example 1
Preparation and Polymerisation of Compound No . 1 in Table 1 Step 1
DCC/DMAP
Meso-butan-1 , 2 , 3 , 4-tetracarboxylic acid (20 . Og, 0 . 0428 mol ) , diallylamine ( 39 . Og, 0 .20 mol ) , 1 , 3- dicyclohexylcarbodiimide (82.50g, 0.20 mol) and 4- dimethylaminopyridine (2.0mg) were dissolved in dichloromethane/tetrahydrofuran (1:1) mixture (200 cm3) and the mixture was stirred at room temperature for 120 hours. 1,3- dicyclohexylurea was removed by filtration and the solvent removed in vacuo to leave a yellow oil. Column chromatography (silica gel/ethyl acetate) followed by removal of solvent in vacuo gave a heavy pale yellow oil which solidified on standing. 42.3g, 89%.
XHNMR (CDCl3)δ: 2.90 (m, 4H) , 3.50(m, 2H) , 3.80(m, 16H) , 5.20(m, 16H), 5.70(m, 8H)
Ir vmax (thin film) : 3323, 3086, 2935, 2861, 1650, 1545, 1416, 1363, 1228, 1135, 994, 925, 556 cm'1
Step 2
Monomer from Step 1 (l.Og) was dissolved in dry dichloromethane (3cm3) . The Irgacure 184 (lOmg) was added to the solution, heated and mixed to ensure homogenicity . It was then spread evenly on an 18 x 25 cm glass plate and the solvent allowed to evaporate off to leave a thin, clear film. This was irradiated with a Philips UVA sunlamp for 30 minutes to form a hard cross- linked polymer film. This was removed (scalpel) , washed in dichloromethane and dried. Yield 0.64g, 64%.
Ir vmax (thin film): 3424, 2936, 2374, 2346, 1705, 1644 (s),
1524, 1436(s), 1222, 1138, 992, 924, 561 cm'1
Example 2
Preparation of Compound No . 3 in Table 1
Amide A (23.21g, 0.11 mol), pentaerythritol (3.75g, 0.028 mol), dicyclohexylcarbodiimide (22.70g, 0.11 mol) and 4- dimethylaminopyridine (0.50g) were placed in
THF/dichloromethane mixture (1:1) and left stirring at room temperature for 5 days. The resultant dicyclohexylurea was removed by filtration and the solvent removed in vacuo to leave a yellow oil. Column chromatography using silica gel and ethyl acetate followed by methanol gave, after removal of solvent in facuo 23.6g, 95% of pale yellow oil. Ir vmax (thin film): 2938, 1743(s), 1649(s), 1417, 1225, 1149, 996, 926, 559 cm'1.
XHNMR (CDC13) δ: 1.95(quin, 8H) , 2.40 (quartet, 16H) , 3.88 (d,
8H) , 3.97(d, 8H) , 4.10(s, 8H) ,
5.16(m, 16H) , 5.77 (m, 8H) .
Example 3
Preparation of Compound No. 4 in Table 1
Tris (2-aminoethyl) amine (2.08g, 0.0142 mol) and dicyclohexylcarbodiimide (8.87g, 0.043 mol) were placed in dry dichloromethane (100 cm3) and stirred at room temperature. Amide A (9.0g, 0.043 mol) in dry dichloromethane (20 cm3) was added dropwise over 30 minutes and the whole was left to stir for five days. The dicyclohexylurea was removed by filtration (Whatman No. 1 filter paper) and the solvent removed in vacuo to leave a yellow oil. The oil was purified using chromatography (ethyl acetate followed by methanol) Removal of solvent gave a pale yellow oil, 8.94g, 87%.
Ir vmax (thin film): 3321 (s), 3086, 2934, 1620, 1551, 1420, 1358, 1234, 1136, 1060, 994, 927, 756, 665, 560 cm"1.
XHNMR (CDC13) δ: 1.95(quin, 6H) , 2.28 (t, 6H) , 2.41 (t, 6H) , 2.56(t, 6H) , 3.26(q, 6H) , 3.95(d, 6H) , 3.96(d, 6H) , 5.14(m, 12H) , 5.75 (m, 6H) , 7.28(t, 3H) .
Example 4
Preparation of Compound No. 5 in Table 1
Triethanolamine (5.10g, 0.034 mol), Amide A (20. Og, 0.10 mol), dicyclohexylcarbodiimide (20.60g, 0.10 mol) and 4- dimethylaminopyridine (0.5g) were dissolved in dry dichloromethane and the solution stirred for 48 hours. The resultant dicyclohexylurea was removed by filtration and the solvent removed in vacuo to leave a yellow oil. The oil was redissolved in dichloromethane and washed with 3M HCl solution (100 ml), then brine (100 ml), then dried over MgS04. The solvent was removed in vacuo to leave an oil which was purified via column chromatography using silica gel with ethyl acetate as the eluent. Removal of solvent in vacuo left 21.4g, 91% as a pale yellow oil.
Ir vmax (thin film): 3087, 2932, 1738, 1654, 1416, 1223, 1169, 995, 927, 755, 666, 557 cm"1.
^NMR (CDC13) δ: 2.65(m, 12h) , 2.85(t, 6H) , 3.90(d, 6H) , 3.98 (d, 6H) , 4.13(t, 6H) , 5.10 (m, 12H) , 5.76(m, 6H) .
Example 5
Preparation of Compound No. 6 in Table 1
Phlorglucinol dihydrate (5.0g, 0.031 mol), amide A (15.43g,
0.095 mol), dicyclohexylcarbodiimide (19.60g, 0.095 mol) and 4- dimethyla inopyridine (0.5g) were placed in dry dichloromethane and stirred for 48 hours at room temperature. Dicyclohexylurea was removed by filtration and the solvent removed in vacuo to leave a clear oil. Column chromatography using silica gel and ethyl acetate followed by removal of solvent in vacuo gave a clear oil, 16.40g, 76%. Ir vmax (thin film): 3088, 3016, 2932, 1769(s), 1656(s), 1417, 1369, 1226, 1131, 997, 927, 756, 667, 556 cm"1.
'HNMR (CDCI3) δ: 2.72 (t, 6H) , 2.88 (t, 6H) , 3.91m, 6H) , 4.00 (m, 6H) , 5.15(m, 12H) , 5.76(m, 6H) , 6.80(s, 3H) .
Example 6
Preparation of Compound No. 7 in Table 1
CH2COOH /" DCC/DMAP
HO— j-COOH + H_N ^
CH2COOH
Citric acid (10. Og, 0.048 mol) and diallylamine (14. Og, 0.145 mol) were carefully placed in 25 cm3 THF-Dichloromethane (1:1) and stirred for 30 minutes. Dicyclohexylcarbodiimide (25 cm3) (30. Og, 0.145 mol) was added slowly and carefully to the reaction mixture. Finally 4-dimethylaminopyridine (l.Og) was added and the mixture was stirred at room temperature for 8 days. Thin layer chromatography (ethyl acetate) showed a major new product and several smaller ones. The dicyclohexylurea was removed by filtration (Whatman No. 1 filter paper) and the solvent removed in vacuo to leave a yellow oil. The oil was redissolved in dichloromethane (150 cm3) and washed with (i) 3M HCl solution (100 cm3), (ii) 3M Na2C03 solution (100 cm3), (iii) brine (100 cm3), then dried over MgSθ4. Removal of solvent in vacuo left a yellow oil which was dried thoroughly to leave 12.37g, 58% of product. Ir vmax (thin film): 3294, 3086, 2987, 1737 (w) , 1637 (s), 1400 1345, 1228, 1137, 995, 921, 756, 690 cm"1.
XHNMR (CDC13) δ: 2.24(s, 4H) , 3.20(s, br, 1H) , 3.88(d, 6H) , 3.99(d, 6H) , 5.20 (m, 12H) , 5.78(m, 6H) .
Example 7
Preparation of Polymer Composite
Compound A
^Λ o II
C(CF2)3COOH
184/hv
(Hard Lacquer) Polymer (on glass)
Compound B
Monomers A (0.5g) and B (0.025g) were dissolved with the Irgacure 184 (25mg) in dry dichloromethane (2 cm3) and the solution spread over an area 3 x 7 cm on a plate glass plate. The solvent was allowed to evaporate to leave a thin monomer film which was irradiated with a Philips UVA (75w) sunlamp for 1 hour. The resultant hard polymer film was washed with dry dichloromethane (20 cm3) to remove surface stickiness and allowed to dry in air.

Claims

Claims
A poly (diallylamine) polymer comprising a repeat unit derived from a monomer of the general formula I:
or la :
wherein R1 and R2 are independently selected from (CR7R8)n, or a group CR9R10, - (CR7R8CR9R10) - or - (CR9R10CR7R8) - where n is 0,1 or 2, R7 and R8 are independently selected from hydrogen or alkyl, and either (a) one of R9 or R10 is hydrogen and the other an electron withdrawing group, or (b) R9 and R10 together form an electron withdrawing group;
R3 and R4 are independently selected from C, CH or CR11, where R11 is an electron withdrawing group;
the dotted lines indicate the presence or absence of a bond, and X is a group CX^X2 where the dotted line bond to which it is attached is absent and a group CX1 where the dotted line bond to which it is attached is present, Y is a group CY1Y2 where the dotted line bond to which it is attached is absent and a group CY1 where the dotted line bond to which it is attached is present, and X1, X2, Y1 and Y2 are independently selected from hydrogen and fluorine; R5 is either a bond or an electron withdrawing group;
R6 is a bridging group of valency r;
r is an integer of 3 or greater;
R12 is H, or an optionally substituted hydrocarbyl group; and
z" is an anion of valency m,
or a pharmaceutically acceptable derivative of such a polymer, for use in any surgical, therapeutic or diagnostic method practised on a human or animal patient.
2. A poly (diallylamine) polymer or derivative as defined in claim 1, for use as a bile acid remover for administration to a human or animal patient.
3. A poly (diallylamine) polymer or derivative as defined in claim 1, for use in reducing serum cholesterol levels in a human or animal patient.
4. A poly (diallylamine) polymer or derivative as defined in claim 1, for use according to any one of claims 1 to 3, wherein in formula I or la, R1 and R are both CH2.
5. A poly (diallylamine) polymer or derivative as defined in claim 1 or claim 4, for use according to any one of claims 1 to 3, wherein in formula I or la, R3 and R4 are both CH .
6. A poly (diallylamine) polymer or derivative as defined in any one of claims 1, 4 or 5, for use according to any one of claims 1 to 3, wherein in formula I or la, X1, X2, YJ and Y4 are all hydrogen.
7. A poly (diallylamine) polymer or derivative as defined in any one of claims 1, 4, 5 or 6,, for use according to any one of claims 1 to 3, wherein in formula I or la, r is from 3 or 4.
8. A poly (diallylamine) polymer or derivative as defined in any one of claims 1 or 4 to 7, for use according to any one of claims 1 to 3, wherein in formula I or la, R12 is a hydrophobic group.
9. A poly (diallylamine) polymer or derivative as defined in any one of claims 1 or 4 to 8, for use according to any one of claims 1 to 3, wherein in formula I or la, R and/or R are electron withdrawing, activating groups.
10. A poly (diallylamine) polymer or derivative as defined in any one of claims 1 or 4 to 9, , for use according to any one of claims 1 to 3, wherein in formula I or la, Z" is chloride or bromide .
11. A poly (diallylamine) polymer or derivative as defined in any one of claims 1 or 4 to 10, for use according to any one of claims 1 to 3, wherein the compound of formula I or la is able to cyclopolymerise under the influence of ultraviolet or thermal radiation.
12. A poly (diallylamine) polymer or derivative as defined in any one of claims 1 or 4 to 11, for use according to any one of claims 1 to 3, wherein in formula I or la, the diallyl amino nitrogen and R5 together form an electron withdrawing group.
13. A poly (diallylamine) polymer as defined in claim 1, for use according to any one of claims 1 to 3, the polymer comprising a repeat unit derived from a monomer of the general formula II:
wherein R , R" R , 23 and R are each groups of sub-formula I I I
where X , X , Y , Y , R , R% R , R and RD are as defined in claim
1 ;
R25, R26, R27 and R28 are each independently selected from hydrogen or a hydrocarbyl group; the compound optionally contains a metal ion within the macrocyclic heterocyclic unit; and
R17, R18, R19 and R20 are independently selected from groups of sub-formula IV:
where a and b are independently selected from 0, 1 or 2, Z , Z-" and Z3 are independently selected from a bond, an optionally substituted linear or branched alkyl or alkene chain wherein optionally one or more non-adjacent carbon atoms is replaced with a heteroatom or an amide group, and Q1 and Q2 are independently selected from an optionally substituted carbocyclic or heterocyclic ring which optionally contains bridging alkyl groups.
14. A poly (diallylamine) polymer as defined in claim 13, for use according to any one of claims 1 to 3, wherein in formula
I I , R 17 R1 R19 and R20 are al kyl groups
15. A poly (diallylamine) polymer as defined in claim 1, for use according to any one of claims 1 to 3, the polymer comprising a repeat unit derived from a monomer of the general formula V:
wherein R50 through to R65 are independently selected from hydrocarbyl, a group OR68 where R68 is hydrocarbyl or halogen, or a group R21-R24 where R21 and R24 are as defined in claim 13, provided that at least three of R50 to R65 are R21-R24 groups; and R66 and R67 are either hydrogen or together comprise a metal ion.
16. A poly (diallylamine) polymer as defined in claim 15, for use according to any one of claims 1 to 3, wherein in formula
V , R51 , R52, R 55
R° ,59 R 60 R63 and R64 are halogen and R50, R53,
R 57 R 58 Rc R and R are independently C1-12 alkyl, C1-12 alkoxy or a group R 1-R24
17. A poly (diallylamine) polymer accas defined in claim 1, for use according to any one of claims 1 to 3, wherein the polymer comprises a repeat unit derived from a monomer of the general formula VI :
where R17, RI8,R19, R20, R21, R22, R23 and R24 are as defined in ccllaaiimm 1133;; RR2288,, RR2299,, RR3300 aanndd :R31 are hydrocarbyl groups; and s is 0 or an integer of 1 or more,
18. A poly (diallylamine) polymer as defined in claim 17, for use according to any one of claims 1 to 3, wherein the monomer of formula VI has four siloxane units in the ring (i.e. s is 1) -
19. A poly (diallylamine) polymer as defined in claim 17 or claim 18, for use according to any one of claims 1 to 3, wherein in formula VI, -Si- is replaced by B or B"; or -Si-O- is replaced by -B-N(R where R ,40 is a hydrocarbyl group.
20. A poly (diallylamine) polymer as defined in claim 1, for use according to any one of claims 1 to 3, wherein the polymer is of the formula VII:
R24
where R17, R18,R19, R20, R21, R22, R23 and R24 are as defined in claim 13.
21. A poly (diallylamine) polymer as defined in claim 1, for use according to any one of claims 1 to 3, wherein in formula I or la, R6 is selected from the group consisting of:
>CH-CH<
-CH2CHCHCH2-
N[ (CH2)2NHC(0) (CH2)3-]3
N[ (CH2)20C(0) (CH2)3-]3
-CH2C ( 0H ) CH2-
C ( O ) -
22. A poly (diallylamine) polymer as defined in claim 1, for use according to any one of claims 1 to 3, the polymer being derived from a monomer which is substantially as herein described.
23. The use of a polymer as defined in any one of claims 1 or 4 to 22, or of a pharmaceutically acceptable derivative of such a polymer, in the preparation of a medicament for use in any surgical, therapeutic or diagnostic method practised on a human or animal patient.
24. Use according to claim 23, wherein the medicament is for use as a bile acid remover for administration to a human or animal patient.
25. Use according to claim 23 or claim 24, wherein the medicament is for use in reducing serum cholesterol levels in a human or animal patient.
26. A method of treatment of a human or animal patient to reduce bile acid levels, the method comprising administering to the patient a therapeutically effective amount of a poly (diallylamine) polymer as defined in any one of claims 1 or 4 to 22, or of a pharmaceutically acceptable derivative of such a polymer.
27. A method of treatment of a human or animal patient to reduce serum cholesterol levels, the method comprising administering to the patient a therapeutically effective amount of a poly (diallylamine) polymer as defined in any one of claims 1 or 4 to 22, or of a pharmaceutically acceptable derivative of such a polymer.
28. A pharmaceutical composition containing a poly (diallylamine) polymer as defined in any one of claims 1 or 4 to 22, or a pharmaceutically acceptable derivative of such a polymer, together with a pharmaceutically acceptable excipient.
29. A method for producing a pharmaceutical composition according to claim 28, the method comprising causing a monomer of formula I or la to polymerise, and admixing the resultant polymer with one or more pharmaceutically acceptable adjuvants.
EP00974674A 1999-11-17 2000-11-10 Use of poly(diallylamine) polymers Expired - Lifetime EP1265942B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9927088.6A GB9927088D0 (en) 1999-11-17 1999-11-17 Use of poly(diallylamine) polymers
GB9927088 1999-11-17
PCT/GB2000/004308 WO2001036510A2 (en) 1999-11-17 2000-11-10 Use of poly(diallylamine) polymers

Publications (2)

Publication Number Publication Date
EP1265942A2 true EP1265942A2 (en) 2002-12-18
EP1265942B1 EP1265942B1 (en) 2005-01-26

Family

ID=10864611

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00974674A Expired - Lifetime EP1265942B1 (en) 1999-11-17 2000-11-10 Use of poly(diallylamine) polymers

Country Status (9)

Country Link
US (1) US7767229B1 (en)
EP (1) EP1265942B1 (en)
JP (1) JP2003514935A (en)
AT (1) ATE287911T1 (en)
AU (1) AU772653B2 (en)
CA (1) CA2391539C (en)
DE (1) DE60017805T2 (en)
GB (1) GB9927088D0 (en)
WO (1) WO2001036510A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010002141A1 (en) 2010-02-19 2011-08-25 Momentive Performance Materials GmbH, 51373 Integral Irradiation Unit
WO2013024146A1 (en) 2011-08-18 2013-02-21 Momentive Performance Materials Gmbh Irradiating and molding unit

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606016D0 (en) * 2006-03-25 2006-05-03 Ionic Polymer Solutions Ltd Quaternary ammonium compounds and their uses
GB0613013D0 (en) 2006-06-30 2006-08-09 Novel Polymer Solutions Ltd Polymeric Materials and Methods for Manufacturing Them
WO2012017235A1 (en) 2010-08-02 2012-02-09 Novel Polymer Solutions Limited Covered floors and methods of adhering flooring to a floor
WO2012017237A1 (en) 2010-08-02 2012-02-09 Novel Polymer Solutions Limited Composite articles and methods of producing same
EP2601047B8 (en) 2010-08-02 2015-02-25 Syntor Specialty Chemicals Limited Methods of coating a low surface energy substrate
SI3400944T1 (en) 2010-11-08 2020-11-30 Albireo Ab Ibat inhibitors for the treatment of liver diseases
GB201105453D0 (en) 2011-03-31 2011-05-18 Novel Polymer Solutions Ltd Window frames, structural elements for a roofed construction and methods of assembling same
GB201115823D0 (en) 2011-09-13 2011-10-26 Novel Polymer Solutions Ltd Mineral processing
CN104640681B (en) 2012-06-11 2017-11-17 迈图高新材料集团 Method for preparing plastics composite shaped body
DK3003327T3 (en) 2013-06-05 2017-10-23 Tricida Inc PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION
JP6751020B2 (en) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 Solid preparation and method for preventing or reducing coloration thereof
DK3593808T3 (en) 2014-12-10 2021-02-01 Tricida Inc PROTON BINDING POLYMER FOR ORAL ADMINISTRATION
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
CN111032019B (en) 2017-08-09 2022-07-05 阿尔比里奥公司 Cholestyramine granules, oral cholestyramine preparation and application thereof
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
EP3802504B1 (en) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
WO2019245449A1 (en) 2018-06-20 2019-12-26 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
ES2972045T3 (en) 2019-12-04 2024-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
FI4069360T3 (en) 2019-12-04 2024-02-20 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2973355T3 (en) 2019-12-04 2024-06-19 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (en) 2020-11-12 2023-11-22 アルビレオ エービー Odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE520401A (en) * 1952-06-03
US3957699A (en) * 1973-06-12 1976-05-18 Ici Australia Limited Process for polymerizing allylamines employing a redox initiator consisting of Fe++ or Ti+++ with H2 O2, hydroxyl amine, or hydroperoxides to form insoluble crosslinked polymers
US4121986A (en) * 1975-05-07 1978-10-24 Ici Australia Limited Process for the polymerization of polyallylamines in the presence of a mineral acid solution
JPS5747302A (en) * 1980-09-03 1982-03-18 Mitsubishi Petrochem Co Ltd Preparation of crosslinkable electrolytic polymer
JPS62257481A (en) * 1986-04-30 1987-11-10 三洋化成工業株式会社 Dye fixing agent
US4759923A (en) * 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JPH021358A (en) * 1988-03-01 1990-01-05 Sanyo Chem Ind Ltd Chemical for ink jet recording paper
US6203785B1 (en) * 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
SG105450A1 (en) * 1998-07-02 2004-08-27 Nat Starch Chem Invest Allylated amide compounds and die attach adhesives prepared therefrom
SG85658A1 (en) * 1998-07-02 2002-01-15 Nat Starch Chem Invest Package encapsulants prepared from allylated amide compounds
GB9816171D0 (en) * 1998-07-25 1998-09-23 Secr Defence Monomers and network polymers obtained therefrom
GB9816167D0 (en) * 1998-07-25 1998-09-23 Secr Defence Polymer production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0136510A2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010002141A1 (en) 2010-02-19 2011-08-25 Momentive Performance Materials GmbH, 51373 Integral Irradiation Unit
WO2011101269A1 (en) 2010-02-19 2011-08-25 Momentive Performance Materials Gmbh Integral irradiation unit
WO2013024146A1 (en) 2011-08-18 2013-02-21 Momentive Performance Materials Gmbh Irradiating and molding unit

Also Published As

Publication number Publication date
AU1289301A (en) 2001-05-30
EP1265942B1 (en) 2005-01-26
US7767229B1 (en) 2010-08-03
WO2001036510A2 (en) 2001-05-25
DE60017805D1 (en) 2005-03-03
GB9927088D0 (en) 2000-01-12
AU772653B2 (en) 2004-05-06
DE60017805T2 (en) 2006-01-12
WO2001036510A3 (en) 2002-09-12
ATE287911T1 (en) 2005-02-15
CA2391539A1 (en) 2001-05-25
JP2003514935A (en) 2003-04-22
CA2391539C (en) 2009-08-11

Similar Documents

Publication Publication Date Title
EP1265942B1 (en) Use of poly(diallylamine) polymers
Lele et al. Mucoadhesive drug carriers based on complexes of poly (acrylic acid) and PEGylated drugs having hydrolysable PEG–anhydride–drug linkages
EP2175866B1 (en) Novel one step process for preparing cross-linked poly(allylamine) polymers
JP4130305B2 (en) Polyanhydrides with therapeutically useful degradation products
AU740380B2 (en) Strictly alternating poly(alkylene oxide ether) copolymers
EP1246627B1 (en) Polyanhydrides with biologically active degradation products
US8852640B2 (en) Micelles for delivery of nitric oxide
US7411031B2 (en) Synthesis of polyanhydrides
JP2003514935A5 (en)
AU2006292752A1 (en) Polymeric compositions and methods of making and using thereof
WO2006115293A1 (en) NOVEL BLOCK COPOLYMER USED FOR PREPARING pH-RESPONSIVE POLYMER MICELLE, AND METHOD FOR PRODUCING SAME
JP4465193B2 (en) Phosphate transport inhibitor
CN113456827A (en) Nano material and preparation method and application thereof
JP7410575B2 (en) Levodopa derivatives and their uses
CN108815536B (en) Drug delivery material with pH and dual redox responsiveness and preparation method and application thereof
JPS58149903A (en) Neocarcinostatin complex and its production
Zhao Precision and Rational Engineering of Bio-Inspired Hierarchical Polymeric Networks for Biomedical Engineering Applications
JP4699635B2 (en) Sustained release pharmaceutical composition
JP6654057B2 (en) Composition for controlling local pain comprising a polyion complex containing a local anesthetic as an active ingredient
JP2003176318A (en) Radical-polymerizable 2-imidazoline derivative and method for producing the same
CN111388453A (en) Preparation method of sunitinib nano-drug capsule with pH and reduction cascade dual responses
JPH01213321A (en) Production of novel thin film polymer
JPH0892314A (en) 2,5-bis-(1-aziridinyl)-p-benzoquinone-polymeric complex

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020511

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20031030

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050126

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050126

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050126

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050126

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050126

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050126

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050126

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050126

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050126

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60017805

Country of ref document: DE

Date of ref document: 20050303

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050426

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050426

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050426

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051110

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051130

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051130

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

ET Fr: translation filed
26N No opposition filed

Effective date: 20051027

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050626

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20091120

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20091201

Year of fee payment: 10

Ref country code: GB

Payment date: 20091119

Year of fee payment: 10

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20101110

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110801

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60017805

Country of ref document: DE

Effective date: 20110601

Ref country code: DE

Ref legal event code: R119

Ref document number: 60017805

Country of ref document: DE

Effective date: 20110531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531